Haemonetics Corp (HAE)

Currency in USD
81.66
+2.86(+3.63%)
Real-time Data·
HAE is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
77.4681.99
52 wk Range
47.3287.32
Key Statistics
Prev. Close
78.8
Open
78.68
Day's Range
77.46-81.99
52 wk Range
47.32-87.32
Volume
1.12M
Average Volume (3m)
839.84K
1-Year Change
14.3756%
Book Value / Share
17.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HAE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
81.60
Downside
-0.07%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Haemonetics Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

8 Buy
3 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 81.60
(-0.07% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Hold70.00-14.49%64.00Maintain28/05/2026
BofA Securities
Buy80.00-2.27%72.00Upgrade22/05/2026
Baird
Buy67.00-18.15%72.00Maintain08/05/2026
Baird
Buy72.00-12.04%81.00Maintain15/04/2026
BTIG
Buy84.00+2.61%88.00Maintain13/04/2026

Haemonetics Corporation Earnings Call Summary for Q4/2026

  • Q4 adjusted EPS of $1.29 beat forecast of $1.27; revenue hit $346M vs. $337M expected, driving 9.51% pre-market stock surge to $57.50.
  • Full-year revenue reached $1.3B with adjusted EPS of $4.96, up 9% YoY; Q4 operating margin declined 50 bps to 24.4% amid tariff headwinds.
  • FY2027 guidance projects 4-7% reported revenue growth and 3-6% organic growth, driven by plasma and blood management technology expansion.
  • Strategic product launches including Persona PLUS and PerQseal Elite expected to fuel growth; hospital business targeting mid-single-digit gains.
  • Key risks include tariff impacts on margins, supply chain disruptions, regulatory approval delays, and competitive pressures in core markets.
Last Updated: 07/05/2026, 14:40
Read Full Transcript

Earnings

Latest Release
07/05/2026
EPS / Forecast
1.29 / 1.27
Revenue / Forecast
346M / 337.04M
EPS Revisions
Last 90 days

Compare HAE to Peers and Sector

Metrics to compare
HAE
Peers
Sector
Relationship
P/E Ratio
38.2x15.0x−0.5x
PEG Ratio
−0.97−0.140.00
Price/Book
4.7x1.4x2.6x
Price / LTM Sales
2.8x1.8x3.0x
Upside (Analyst Target)
4.1%45.0%58.6%
Fair Value Upside
Unlock4.7%10.2%Unlock

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
24.60M54.13%1.94B
Other Institutional Investors
23.68M45.87%1.87B
Public Companies & Retail Investors
0.000.00%0.00
Total
48.28M100.00%3.8B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.12.37%5,619,979442,854
Neuberger Berman Investment Advisers LLC7.84%3,560,918280,600

People Also Watch

58.47
AOS
+2.18%
99.32
LRN
-0.52%
148.48
Q
+6.25%
130.81
BMI
+1.85%

FAQ

What Is the Haemonetics (NYSE: HAE) Share Price Today?

The Haemonetics stock price today is 81.66 USD.

What Stock Exchange Does Haemonetics (HAE) Trade On?

Haemonetics is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Haemonetics?

The stock symbol (also called a 'ticker') for Haemonetics is "HAE."

What Is the Current Haemonetics Market Capitalisation?

As of today, Haemonetics (NYSE: HAE) market cap is 3.71B USD.

What Is Haemonetics's (HAE) Earnings Per Share (TTM)?

The Haemonetics EPS is currently 2.05 (Trailing Twelve Months).

When Is the Next Haemonetics Earnings Date?

Haemonetics's next earnings report will be released on 11/08/2026.

Is HAE a Buy or Sell From a Technical Analyst Perspective?

Based on today's Haemonetics moving averages and other technical indicators, the daily buy/sell signal for HAE stock is Strong Buy.

How Many Times Has Haemonetics Stock Split?

Haemonetics has split 2 times. (See the HAE stock split history page for full effective split date and price information.)

How Many Employees Does Haemonetics Have?

Haemonetics has 3009 employees, based on their latest Companies House report.

What is the current trading status of Haemonetics (NYSE: HAE)?

As of 11/06/2026, Haemonetics (HAE) is trading at a share price of 81.66 USD, with a previous close of 78.80 USD. The stock has fluctuated within a day range of 77.46 USD to 81.99 USD, while its 52-week range spans from 47.32 USD to 87.32 USD.

What Is Haemonetics (HAE) Price Target According to Analysts?

The average 12-month price target for Haemonetics is 81.60 USD, with a high estimate of 104 USD and a low estimate of 62 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -0.07% Downside potential.

What Is the HAE Premarket Price?

HAE's last pre-market stock price is 78.72 USD. The pre-market share volume is 11.00, and the stock has decreased by -0.08, or -0.10%.

What Is the HAE After Hours Price?

HAE's last after hours stock price is 78.78 USD, the stock has decreased by -0.02, or -0.03%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.